Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells.
暂无分享,去创建一个
R. Steinman | M. Dhodapkar | D. Nixon | S. M. Donahoe | V. Cerundolo | N. Bhardwaj | P. Dunbar | P R Dunbar | V Cerundolo | D F Nixon | R M Steinman | N Bhardwaj | M Sapp | M V Dhodapkar | H Desai | C Fossella | J Krasovsky | S M Donahoe | M. Sapp | J. Krasovsky | H. Desai | H. Desai | C. Fossella | Coraleen Fossella
[1] Philip J. R. Goulder,et al. Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.
[2] S. Hoffman,et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. , 1998, Science.
[3] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[4] Edgar G. Engleman,et al. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.
[5] F. Sallusto,et al. Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.
[6] E. Jaffee,et al. Cancer Vaccines , 1997, Current protocols in human genetics.
[7] J. Mayordomo,et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity , 1996, The Journal of experimental medicine.
[8] Seah H. Lim,et al. Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] K. Rock,et al. Fully mobilizing host defense: Building better vaccines , 1998, Nature Biotechnology.
[10] R. Steinman,et al. Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors , 1997, The Journal of experimental medicine.
[11] R. Zinkernagel,et al. Antiviral immunity. , 1997, Immunology today.
[12] A. McMichael,et al. Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2 , 1987, Nature.
[13] R. Grant,et al. Activity of a ritonavir plus saquinavir‐containing regimen in patients with virologic evidence of indinavir or ritonavir failure , 1998, AIDS.
[14] L. Zitvogel,et al. Bone Marrow‐Derived Dendritic Cells Serve as Potent Adjuvants for Peptide‐Based Antitumor Vaccines , 1997, Stem cells.
[15] Liangji Zhou,et al. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[16] J. Harris,et al. The human primary immune response to keyhole limpet haemocyanin: interrelationships of delayed hypersensitivity, antibody response and in vitro blast transformation. , 1970, Clinical and experimental immunology.
[17] M. Shapero,et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. , 1998, AIDS research and human retroviruses.
[18] R. Steinman,et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. , 1996, Journal of immunological methods.
[19] G. Murphy,et al. Phase I clinical trial: T‐cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA‐A0201‐specific peptides from prostate‐specific membrane antigen , 1996, The Prostate.
[20] R. Siliciano,et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. , 1998, The Journal of infectious diseases.
[21] R. Steinman,et al. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. , 1994, The Journal of clinical investigation.
[22] R. Steinman,et al. Dendritic cells and the control of immunity , 1998, Nature.
[23] W. Storkus,et al. B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines , 2003 .
[24] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[25] E. Gilboa,et al. Induction of antitumor immunity using bone marrow-generated dendritic cells. , 1996, Journal of immunology.
[26] Polly Matzinger,et al. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.
[27] G. Ogg,et al. Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood , 1998, Current Biology.
[28] N. Bhardwaj,et al. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells. , 1997, Blood.
[29] A. McMichael,et al. Rapid Effector Function in CD8+ Memory T Cells , 1997, The Journal of experimental medicine.
[30] R. Steinman,et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. , 1999, AIDS.
[31] R. Steinman,et al. Antigen presentation and related immunological aspects of HIV-1 vaccines. , 1998, AIDS.